| Dr Ricky Darren Toyama, OD | |
|
Psc 827, Box 1000, Apo, AE 09617-9998 | |
| (011) 390-818116386 | |
| Not Available |
| Full Name | Dr Ricky Darren Toyama |
|---|---|
| Gender | Male |
| Speciality | Optometrist |
| Location | Psc 827, Apo, Armed Forces Europe |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1568636553 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 152W00000X | Optometrist | 0881 (California) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Ricky Darren Toyama, OD Psc 827, Box 1000, Apo, AE 09617-9998 Ph: () - | Dr Ricky Darren Toyama, OD Psc 827, Box 1000, Apo, AE 09617-9998 Ph: (011) 390-818116386 |
News Archive
Right around the time in mid-March when Lehigh University moved to remote learning and researchers began to shut down on-campus labs, Nelson Tansu, the Daniel E. '39 and Patricia M. Smith Endowed Chair Professor in the department of electrical and computer engineering, received an email from Dr. Christopher Roscher, an anesthesiologist at St. Luke's University Health Network.
Aggressive ovarian tumors begin as malignant cells kept in check by the immune system until, suddenly and unpredictably, they explode into metastatic cancer. New findings from scientists at The Wistar Institute demonstrate that ovarian tumors don't necessarily break "free" of the immune system, rather dendritic cells of the immune system seem to actively support the tumor's escape.
Apitope, the drug discovery and development company focused on disease-modifying treatments for patients with autoimmune and allergic diseases, announced today that it has started preclinical development of its novel peptide therapy ATX-GD-459 for the treatment of Graves' disease.
Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, has initiated a Phase 1 study of PV-10 for liver cancer. The study will enroll up to six subjects with cancer metastatic to the liver or with recurrent liver cancer. PV-10 is the company's lead oncology drug candidate that is also currently undergoing Phase 2 study for metastatic melanoma.
› Verified 2 days ago
Le Phan Andrus, O.D. Optometrist Medicare: Not Enrolled in Medicare Practice Location: 52 Mdg, Unit 3690, Apo, AE 09126 Phone: 011-496-565618425 | |
Dr. Bob Sarivannara, O.D. Optometrist Medicare: Not Enrolled in Medicare Practice Location: 48th Mdg, Unit 5115, Apo, AE 09461 Phone: 941-661-5903 | |
Angela Cho, O.D. Optometrist Medicare: Medicare Enrolled Practice Location: 39 Mdg/sgh, Unit 7095, Apo, AE 09824 Phone: 090-676-3344 | |
Amanda Kanwischer Gutierrez, O.D. Optometrist Medicare: Not Enrolled in Medicare Practice Location: 52 Medical Group, Optometry Clinic, Spangdahelm Ab, Germany, Apo, AE 54529 Phone: 210-842-6957 | |
Dr. Clarence David Vesely, O.D. Optometrist Medicare: Not Enrolled in Medicare Practice Location: Landstuhl Regional Medical Center, Cmr 402, Box 2078, Apo, AE 09180 Phone: 011-496-371868532 | |
Dr. James H Hsiau, O.D. Optometrist Medicare: Medicare Enrolled Practice Location: Landstuhl Regional Medical Center, Unit 31000, Apo, AE 09180 Phone: 314-566-5323 | |
Dr. Kristina Lynn Bartee, O.D. Optometrist Medicare: Medicare Enrolled Practice Location: Landstuhl Regional Medical Center Unit 33100, Apo, AE 09180 Phone: 314-636-9754 |